BRPI0716929A8 - tratamento de esclerose múltipla com campath-1h - Google Patents
tratamento de esclerose múltipla com campath-1hInfo
- Publication number
- BRPI0716929A8 BRPI0716929A8 BRPI0716929A BRPI0716929A BRPI0716929A8 BR PI0716929 A8 BRPI0716929 A8 BR PI0716929A8 BR PI0716929 A BRPI0716929 A BR PI0716929A BR PI0716929 A BRPI0716929 A BR PI0716929A BR PI0716929 A8 BRPI0716929 A8 BR PI0716929A8
- Authority
- BR
- Brazil
- Prior art keywords
- campath
- treatment
- multiple sclerosis
- alemtuzumab
- consecutive days
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
tratamento de esclerose múltipla com campath-1 h a presente invenção refere-se a um método para o tratamento de esclerose múltipla (ms) com campath-1 h com eficácia significativa e um perfil de segurança favorável, que oferece uma relação benefício/risco aceitável. descreve-se especialmente o uso de campath-1 h (alemtuzumab) para a produção de um medicamento para o tratamento de esclerose múltipla (ms), compreendendo um primeiro ciclo de tratamento seguido de pelo menos um outro ciclo de tratamento com campath-1 h (alemtuzumab), no qual cada ciclo de tratamento compreende 1-5 doses diárias que são aplicadas em dias consecutivos, em que cada dose diária é > o e menor igual a 12 mg, e em que cada ciclo de tratamento é separado do próximo ciclo em pelo menos 1-24 meses. são descritos também esquemas de tratamento que compreendem a administração de menos do que 12 mg/dia de campath-1 h por um período de 1-5 dias consecutivos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84425106P | 2006-09-13 | 2006-09-13 | |
| EP06090169 | 2006-09-14 | ||
| PCT/EP2007/008084 WO2008031626A1 (en) | 2006-09-13 | 2007-09-11 | Treatment of multiple sclerosis (ms) with campath-1h |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0716929A2 BRPI0716929A2 (pt) | 2013-09-17 |
| BRPI0716929A8 true BRPI0716929A8 (pt) | 2019-02-05 |
Family
ID=38734000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0716929A BRPI0716929A8 (pt) | 2006-09-13 | 2007-09-11 | tratamento de esclerose múltipla com campath-1h |
Country Status (22)
| Country | Link |
|---|---|
| EP (4) | EP2444104A3 (pt) |
| JP (6) | JP5872756B2 (pt) |
| KR (2) | KR101583587B1 (pt) |
| CN (1) | CN102652832A (pt) |
| AR (1) | AR062779A1 (pt) |
| BR (1) | BRPI0716929A8 (pt) |
| CA (1) | CA2662531A1 (pt) |
| CY (1) | CY2016019I2 (pt) |
| DK (1) | DK2066352T3 (pt) |
| ES (2) | ES2917882T3 (pt) |
| HK (1) | HK1136773A1 (pt) |
| HR (1) | HRP20160211T1 (pt) |
| HU (2) | HUE026740T2 (pt) |
| IL (3) | IL197236A (pt) |
| LT (1) | LTC2066352I2 (pt) |
| LU (1) | LU93092I2 (pt) |
| MX (2) | MX2009002660A (pt) |
| PL (2) | PL2066352T3 (pt) |
| PT (2) | PT3028718T (pt) |
| RS (1) | RS54658B1 (pt) |
| SI (1) | SI2066352T1 (pt) |
| WO (1) | WO2008031626A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2444104A3 (en) | 2006-09-13 | 2012-10-24 | Alcafleu Management GmbH & Co. KG | Treatment of multiple sclerosis (MS) with campath-1H |
| US9498528B2 (en) | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
| BRPI1013085A2 (pt) | 2009-05-13 | 2020-11-03 | Genzyme Corporation | imunoglobulinas anti-cd52 humana |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| WO2018195457A2 (en) * | 2017-04-21 | 2018-10-25 | Genzyme Corporation | Treatment of multiple sclerosis with anti-cd52 antibodies |
| WO2020123789A1 (en) * | 2018-12-12 | 2020-06-18 | Pretzer Aboff Ingrid | Vibrational device and methods for mitigating symptoms of freezing of gait |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| EP2444104A3 (en) | 2006-09-13 | 2012-10-24 | Alcafleu Management GmbH & Co. KG | Treatment of multiple sclerosis (MS) with campath-1H |
-
2007
- 2007-09-11 EP EP11189428A patent/EP2444104A3/en not_active Withdrawn
- 2007-09-11 CA CA002662531A patent/CA2662531A1/en not_active Abandoned
- 2007-09-11 ES ES15191491T patent/ES2917882T3/es active Active
- 2007-09-11 EP EP15191491.8A patent/EP3028718B1/en active Active
- 2007-09-11 MX MX2009002660A patent/MX2009002660A/es active IP Right Grant
- 2007-09-11 RS RS20160081A patent/RS54658B1/en unknown
- 2007-09-11 CN CN2012100864372A patent/CN102652832A/zh active Pending
- 2007-09-11 KR KR1020097005111A patent/KR101583587B1/ko active IP Right Grant
- 2007-09-11 PL PL07802348T patent/PL2066352T3/pl unknown
- 2007-09-11 SI SI200731746A patent/SI2066352T1/sl unknown
- 2007-09-11 DK DK07802348.8T patent/DK2066352T3/en active
- 2007-09-11 HU HUE07802348A patent/HUE026740T2/en unknown
- 2007-09-11 PL PL15191491.8T patent/PL3028718T3/pl unknown
- 2007-09-11 WO PCT/EP2007/008084 patent/WO2008031626A1/en active Application Filing
- 2007-09-11 PT PT151914918T patent/PT3028718T/pt unknown
- 2007-09-11 PT PT78023488T patent/PT2066352E/pt unknown
- 2007-09-11 BR BRPI0716929A patent/BRPI0716929A8/pt active Search and Examination
- 2007-09-11 KR KR20157007655A patent/KR20150039879A/ko not_active Application Discontinuation
- 2007-09-11 EP EP07802348.8A patent/EP2066352B1/en active Active
- 2007-09-11 EP EP11189431A patent/EP2433649A3/en not_active Withdrawn
- 2007-09-11 MX MX2013009511A patent/MX354080B/es unknown
- 2007-09-11 JP JP2009527751A patent/JP5872756B2/ja active Active
- 2007-09-11 ES ES07802348.8T patent/ES2563068T3/es active Active
- 2007-09-13 AR ARP070104053A patent/AR062779A1/es not_active Application Discontinuation
-
2009
- 2009-02-25 IL IL197236A patent/IL197236A/en active IP Right Grant
-
2010
- 2010-02-26 HK HK10102029.9A patent/HK1136773A1/xx unknown
-
2013
- 2013-12-02 JP JP2013249139A patent/JP6257287B2/ja active Active
-
2015
- 2015-08-06 IL IL240394A patent/IL240394B/en active IP Right Grant
-
2016
- 2016-02-29 HR HRP20160211T patent/HRP20160211T1/hr unknown
- 2016-05-02 JP JP2016092377A patent/JP2016175929A/ja active Pending
- 2016-05-30 LT LTPA2016019C patent/LTC2066352I2/lt unknown
- 2016-05-30 HU HUS1600028C patent/HUS1600028I1/hu unknown
- 2016-05-31 CY CY2016019C patent/CY2016019I2/el unknown
- 2016-05-31 LU LU93092C patent/LU93092I2/de unknown
-
2017
- 2017-08-01 JP JP2017149006A patent/JP2018024655A/ja active Pending
-
2018
- 2018-02-04 IL IL257341A patent/IL257341A/en unknown
-
2019
- 2019-06-19 JP JP2019113260A patent/JP2019167385A/ja active Pending
-
2021
- 2021-04-14 JP JP2021068079A patent/JP2021107423A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0510094A (pt) | uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos | |
| CY1116041T1 (el) | Μεσα και μεθοδοι για τη θεραπευτικη αγωγη νεοπλασματικων νοσων | |
| BRPI0716929A8 (pt) | tratamento de esclerose múltipla com campath-1h | |
| BR112021015815A2 (pt) | Métodos para tratar colestase | |
| RU2014141180A (ru) | Новое лечение острого лимфобластного лейкоза у детей | |
| BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| BRPI0415639A (pt) | formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| BRPI0609393B8 (pt) | usos de um composto 11-desóxi-prostaglandina | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| BR0314763A (pt) | Tratamento de infecções fúngicas | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| BR112015022538A2 (pt) | terapia de indução de rituximab seguida por terapia de acetato de glatirâmero | |
| BRPI0415953B8 (pt) | formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada | |
| BR112018072339A2 (pt) | tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados | |
| BRPI0520258A2 (pt) | uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina | |
| BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
| TW200719903A (en) | Compositions for the treatment of neoplasms | |
| BR0211830A (pt) | Dose única de azitromicina | |
| BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
| BR112022019846A2 (pt) | Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos | |
| BRPI0511305A (pt) | método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1 | |
| BR112015012497A2 (pt) | combinações farmacêuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: GENZYME CORPORATION (US) , ALCAFLEU MANAGEMENT GMB |
|
| B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: A PETICAO DE NO 20110064524, APRESENTADA EM 20/06/2011, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA, UMA VEZ QUE A ALTERACAO SOLICITADA JA FORA CONSUBSTANCIADA NA RPI NO 2241, DE 17/12/2013. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25E | Requested change of name of applicant rejected |
Owner name: GENZYME CORPORATION (US) , ALCAFLEU MANAGEMENT GMB |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |